Genentech reports detailed OS data for Tecentriq combo in first-line non-squamous NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported additional survival data from the Phase III IMpower150 trial evaluating Tecentriq atezolizumab in 1,202 chemotherapy-naïve patients with advanced stage IV non-squamous non-small cell lung cancer (NSCLC). First-line treatment with Tecentriq plus Avastin bevacizumab, paclitaxel and carboplatin led to a median overall survival (OS), a co-primary endpoint, of 19.2 months vs. 14.7 months for Avastin plus carboplatin and paclitaxel in the intent-to-treat (ITT) population, which excluded patients with anaplastic lymphoma kinase (ALK) or EGFR mutations (n=692) (HR=0.78, 95% CI: 0.64, 0.96, p=0.016).

Genentech said Tecentriq plus chemotherapy without Avastin did not show a significant improvement in OS compared with Avastin plus chemotherapy at the interim analysis (HR=0.88, 95% CI: 0.72, 1.08, p=0.204), and that the trial will continue as planned to the final analysis. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago...